Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PAVmed (PAVM) Other Non-Current Liabilities (2023 - 2025)

PAVmed has reported Other Non-Current Liabilities over the past 3 years, most recently at $6.9 million for Q3 2025.

  • For Q3 2025, Other Non-Current Liabilities changed N/A year-over-year to $6.9 million; the TTM value through Sep 2025 reached $6.9 million, changed N/A, while the annual FY2024 figure was $29.1 million, 34.16% down from the prior year.
  • Other Non-Current Liabilities for Q3 2025 was $6.9 million at PAVmed, up from $6.8 million in the prior quarter.
  • Over five years, Other Non-Current Liabilities peaked at $44.2 million in Q4 2023 and troughed at $260000.0 in Q2 2023.
  • A 3-year average of $13.5 million and a median of $6.8 million in 2025 define the central range for Other Non-Current Liabilities.
  • On a YoY basis, Other Non-Current Liabilities climbed as much as 34.16% in 2024 and fell as far as 34.16% in 2024.
  • Year by year, Other Non-Current Liabilities stood at $44.2 million in 2023, then tumbled by 34.16% to $29.1 million in 2024, then crashed by 76.29% to $6.9 million in 2025.
  • Business Quant data shows Other Non-Current Liabilities for PAVM at $6.9 million in Q3 2025, $6.8 million in Q2 2025, and $6.6 million in Q1 2025.